Company intelligence / Profile preview

Huashen Pharmaceutical

Ownership: Private
Development stage: Other

Overview

The now-dissolved Shijiazhuang/NCPC joint venture developed and commercialized butylphthalide for stroke treatment in China. Other current "Huashen" companies focus on pharmaceutical manufacturing or cosmetic biotech products.

Therapeutic areas: DermatologyNeurology
Modalities: Small molecule drugBiologic/cosmetic ingredients
Industry: Biotech

Drug pipeline

1 asset

jiedu tongmai granule

Unknown

Partnerships

North China Pharmaceutical GroupLong Win FinanceWincentus

Beyond the preview

Go deeper on Huashen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huashen Pharmaceutical.

Explore the full profile